Abstract: Despite advances in our understanding of the pathophysiology and the management of pulmonary arterial hypertension (PAH), significant therapeutic gaps remain for this devastating disease. Yet, few innovative therapies beyond the traditional pathways of endothelial dysfunction have reached clinical trial phases in PAH. Although there are inherent limitations of the currently available models of PAH, the leaky pipeline of innovative therapies relates, in part, to flawed preclinical research methodology, including lack of rigour in trial design, incomplete invasive hemodynamic assessment, and lack of careful translational studies that replicate randomized controlled trials in humans with attention to adverse effects and benefits. Rigorous methodology should include the use of prespecified eligibility criteria, sample sizes that permit valid statistical analysis, randomization, blinded assessment of standardized outcomes, and transparent reporting of results. Better design and implementation of preclinical studies can minimize inherent flaws in the models of PAH, reduce the risk of bias, and enhance external validity and our ability to distinguish truly promising therapies form many false-positive or overstated leads. Ideally, preclinical studies should use advanced imaging, study several preclinical pulmonary hypertension models, or correlate rodent and human findings and consider the fate of the right ventricle, which is the major determinant of prognosis in human PAH. Although these principles are widely endorsed, empirical evidence suggests that such rigor is often lacking in pulmonary hypertension preclinical research. The present article discusses the pitfalls in the design of preclinical pulmonary hypertension trials and discusses opportunities to create preclinical trials with improved predictive value in guiding early-phase drug development in patients with PAH, which will need support not only from researchers, peer reviewers, and editors but also from academic institutions, funding agencies, and animal ethics authorities. (Circ Res.
T he number of scientific publications related to pulmonary hypertension (PH) listed on Pubmed has increased exponentially during the last 2 decades (Figure 1 ). This great interest in preclinical, translational, and clinical research has led to significant advances in our understanding of the pathophysiology 1 and the management 2 of group 1 PH, also called pulmonary arterial hypertension (PAH). Within this period, >10 drugs targeting the endothelin, NO, and prostacyclin pathways 3 were developed and commercialized, decreasing clinical worsening 4 and potentially short-term mortality. 5 However, long-term prognosis of patients with PAH remains poor. [6] [7] [8] Significant translational and therapeutic gaps between preclinical research and improved patients' outcomes thus remain. Unfortunately, few innovative therapies have reached clinical trial phases in PAH, [9] [10] [11] [12] and drug development beyond the traditional pathways of endothelial dysfunction has been unsuccessful. Since the beginning of the millennium, the number of compounds in development and total Research and Development expenditures have increased markedly. 13 Yet, during the same period, the average number of new drugs approved yearly by health authorities has declined.
14 Clinical drug development is notoriously arduous, and there are several possible explanations for the divergence of Research and Development spending and new product approval, including higher regulatory efficacy hurdles, the increased complexity and cost of clinical trials, and the inherent variation and imprecision of clinical studies because of patient heterogeneity. 15 As a result, <5% of high-impact basic science discoveries 16 and <10% of development paths in phase 1 14 are eventually approved by health data reproducibility, 25 and ultimately hinder progress in patients' care. In response to these issues, the National Institutes of Health proposed a set of guidelines and funding policies as minimum reporting requirements to promote rigor, reproducibility, and transparency of preclinical research (Table) .
Although these principles and guidelines have been endorsed by prominent academic societies, associations, and journals with evidence of editorial commitment to complying, [26] [27] [28] recent empirical evidence suggests that such rigor is still lacking in cardiovascular 29 and PH preclinical research. 30 The preclinical phase of research is critical to the decisions made about future drug development. The challenges and pitfalls of early-stage preclinical studies in PAH have been reviewed elsewhere, 19 including the selection and processing of human samples, novel culture technologies, and the advantages and disadvantages of currently available animal models of PH. The present article is an in-depth review addressing the needs for improved methodological rigor and reporting in translational PAH confirmatory research using practical strategies mimicking clinical trial methodologies to enhance reproducibility 
Table. Key Principles and Guidelines for Reporting Preclinical Research Delivered by the National Institutes of Health
Rigorous statistical analysis A section outlining the journal's policies for statistical analysis should be included in the Information for Authors, and the journal should have a mechanism to check the statistical accuracy of submissions.
Transparency in reporting
Journals should have no limit or generous limits on the length of Methods section (including online options) and use a checklist during editorial processing to ensure the reporting of key methodological and analytic information to reviewers and readers, including detailed reporting on the following:
How often each experiment was performed, and whether the results were substantiated by repetition under a range of conditions.
Sample collection to distinguish between independent biological data points and technical replicates.
Statistics, including the statistical test used, exact value of n, definition of center, and dispersion and precision measures.
Whether the samples were randomized, and method of randomization.
Whether experimenters were blind to group assignment and outcome assessment.
Whether an appropriate sample size was computed when the study was being designed and includes the statistical method of computation. If no power analysis was used, include how the sample size was determined.
Criteria that were used for exclusion of any data or subjects.
Similar experimental results that were omitted from the reporting for any reason, especially if the results do not support the main findings of the study.
Outcomes or conditions that were measured or used and are not reported in the Results section.
Data and material sharing
All datasets on which the conclusions of the article rely must be made available on request (where ethically appropriate) during consideration of the manuscript.
Deposition of datasets in public repositories is recommended.
Software should be shared (at the minimum description of whether the software is available and how it can be obtained).
Consideration of refutations
Journals should have a policy stating that if the journal publishes a paper, it assumes responsibility to consider publication of refutations of that paper, according to its usual standards of quality.
Best practice guidelines
Consider establishing best practice guidelines for the following:
Image-based data Description of biological material with enough information to uniquely identify the reagents.
and minimize the risk of advancing a compound to clinical testing that is then proven to have no benefit or to have detrimental effects.
Defining the Programmatic Purpose of Research and Adapting Statistical and Methodological Rigor Accordingly
For obvious reasons, methodological expectations must be appropriately calibrated to the nature and goals of the study (Figure 2 ). The statistical and methodological rigor should thus be adapted according to the nature of the study. In exploratory research, investigators seek to develop pathophysiological theories and identify candidate cellular and molecular signaling pathways/targets implicated in PAH development or progression. Positive findings are generally followed by proofof-concept studies in which the presence of an efficacy signal is hoped. At these stages, avoiding false-negative results by accepting less-rigorous study designs and statistical analyses may be reasonable to increase the sensitivity of detecting a potentially useful therapy at the expense of specificity. 31 However, even at an exploratory stage, attention is required to ensure appropriate sample size is accrued to avoid spurious results and enhance the likelihood of reproducible findings that can be externally validated. In confirmatory investigations, however, researchers seek to provide strong, reproducible, and detailed information using clinically relevant assays and end points. In many ways, confirmatory studies resemble clinical trials, providing data on aspects such as drug dosing, toxicity, and long-term effects of potential drug candidates to decide whether the drug could or should be tested in humans.
Methodological prerequisites for this type of study differ, and the most stringent study design is essential.
Pitfalls in PAH Preclinical Methodological Design
A bias is a systematic error that results in a deviation from the truth and cannot be rectified via study replication or by increasing a study's statistical power. In contrast, imprecision relates to random error. Thus, studies may produce precise but biased results because of flaws in study design and execution. Conversely, a study may be free of significant bias but yield an incorrect effect estimate because of low statistical power (random error). Thoughtful subject eligibility criteria, sample size estimation, randomization, blinding, standardized outcome assessment, proper data handling, and transparent reporting methods address these issues and have profoundly improved the validity of clinical trial results over the years. 32 However, although these design and reporting elements are often considered only in clinical trials, preclinical research is not immune to these same methodological pitfalls. Preclinical scientists should, therefore, consider the impact of study design, data interpretation, and reporting to promote scientific reproducibility and transparency in confirmatory preclinical studies.
Eligibility Criteria: Matching Models to Human Manifestations of PAH
The first step in designing a clinical trial is to define the eligibility criteria with the aim of recruiting a study population representative of future patients to be treated while minimizing confounding effects. Care must thus be taken to enrol experimental animals in studies as patients are Figure 2 . Adaptation of statistical and methodological rigor according to the nature of the study. There is no single type of laboratory study. For confirmatory studies, the most rigorous application of randomized controlled trial-like approaches should be applied, including prespecified study design and statistical analysis plan, describing eligibility criteria, sample size calculation, relevant study read-outs, interim analysis (if any), and corrections for multiple analyses, as well as randomization and concealment procedures, validation of the results, and potentially study preregistration. However, this type of approach may be expensive and cumbersome, and applying randomized controlled trial-like standards to studies focusing on discovery and elucidating fundamental biological processes may not add the same level of value. Thus, expectations and methodological rigor must be appropriately calibrated to the goals of the study. In all cases, however, the choice of an appropriate animal model that is representative of the human disease, the development of standardized operating procedures, blinded outcome assessment, and transparent reporting is critical.
enrolled in clinical trials with attention to reporting results from all animals studied and to prespecify inclusion and exclusion criteria for analysis. In addition to the substantial limitations of current animal models that are beyond the scope of the current review, 19, 33 variations in disease induction and the potential for persistent and unrecognized confounders represent other important sources of bias. Even when using a well-recognized animal model of PH, there are considerable inconsistencies in animals' age and weight, how PH is induced (eg, route and dose of the inducing agent), 34, 35 duration of hypoxia, and when the intervention is initiated and terminated. 30 This is particularly of concern because PH severity has been shown to increase progressively over time before spontaneously improving or even resolving when hypoxic models are returned to normoxic condition, as in weeks after low-dose monocrotaline 36 or Sugen 37, 38 injections. Similarly, experimental PH is more sensitive to preventive strategies compared with reversal strategies, 30 likely influencing the predictability of the model. In studying a preclinical therapy for PAH, it is, therefore, reasonable to randomize animals to therapy when irreversible PH is expectedly fully established and following prior confirmation (eg, pulmonary artery acceleration time <25 ms as evidence of PH).
The high degree of experimental control that is possible in preclinical research can reduce the interindividual variability and, therefore, the sample sizes required relative to clinical studies. This is in marked contrast with the heterogeneous responses observed in most clinical trials as a result of the diverse phenotypic and genetic backgrounds in the patients. 12, 39 In addition to the inconsistencies in animal models described above, there can be striking differences in cardiovascular responses to stimuli in different strains 40 because of both genetic and epigenetic differences in the animals. For these reasons, the rationale for choosing models should be stated, 41, 42 and performing studies using >1 model is recommended, whenever possible, before proceeding to human studies. However, studies not only across different models of PH but also across animal strains are encouraged. The recent establishment of the hybrid mouse diversity panel may be extremely helpful in beginning to address some of these issues. 43 Ultimately, large animal models, such as pigs, 44, 45 the neonatal chronic hypoxia calf model, 46, 47 or nonhuman primates, 48 may share some common features of the human disease, including right heart failure and the development of complex vascular lung lesions. Indeed, preclinical testing in large animal models is often the last step before translating novel drug candidates to clinical trials, for both safety and efficacy assessment. 49 However, current large animal models have been limitedly exploited in PAH research because of incomplete recapitulation of the human phenotype or high mortality. 50, 51 Human ex vivo model systems are also rapidly emerging strategies to study human disease pathogenesis and response to pharmacological intervention, including in PAH. 12 Similarly, engineered 3-dimensional lung tissue constructs that mimic complex tissue physiology have amazing potential for use as lung physiology or disease pathology models, but models requiring large number of cells, multiple cell populations, or use of specific extracellular components or natural scaffolds are often not suitable for the generation of standardized microfluidics-based high-throughput systems for drug discovery or toxicity testing. 52, 53 Importantly, increasing methodological and reporting rigor of studies using inappropriate animal models is unlikely to better inform the scientific community about mechanisms and therapeutic interventions in human PAH. We would argue, however, that if the findings in a single robust model fully support extensive data acquired from human tissues and cells, adding further animal models may not be justified. Conversely, not all laboratories have access to human cells and tissues, and they may make fundamental discoveries with translational potential using animal cells and models but need to acknowledge the lack of corroborative human studies as a limitation.
The need to include women in clinical trials is now a well-established requirement. 54 However, analogous standards have not been equally enforced in preclinical stages of research. This is especially problematic in PAH where there is a significant female predominance in humans, 55 and preclinical data have confirmed the impact of female hormones on the disease. 56 Nevertheless, the vast majority of preclinical PH studies use male rodents ( Figure 3) . 30, 57 Arguments put forward for the preferential use of males include variability attributable to fluctuating gonadal hormone levels, sample size implications of planning sex-based analyses, and cost. 58, 59 Yet, evidence to support these concerns is limited. 60 Furthermore, there is an important distinction between adequately powering a study for detailed sex-based analyses of results and including sufficient animals of both sexes to detect large differences between them, if present. 59 Although the former is valuable, the latter may be sufficient in many instances. 61 Inferring experimental findings to both sexes when a single sex is studied could disadvantage women by biasing our understanding of disease processes toward malepredominant patterns.
Control groups may either be placebo concurrent, no-treatment concurrent, active-treatment concurrent, or dose/timing comparison concurrent. It is required, however, that investigators use a concurrent control for each intervention group. Importantly, new targets can be alternatives to the currently approved therapies in humans even if they do not have additive effects (eg, for nonresponders). However, the landscape of clinical trials in PAH dramatically changed during the last decade. Sequential or upfront combination therapy is now an emerging standard of care in PAH. 2, 62 For ethical reasons, future compounds will, therefore, almost necessarily be tested on top of currently available therapies in clinical trials leading to drug approval. As for placebo-controlled trials in humans, the demonstration of additive or even synergic effects of novel therapeutic targets nowadays seems essential for confirmatory preclinical studies.
Therefore, a detailed characterization and reporting of animal traits at baseline (species, strain, age, sex, genetic modification status, housing conditions, etc), of appropriate controls (littermate, purchased, contemporaneous versus historical, etc) using animal characteristics that are representative of the human disease should thus be promoted for a better standardization of the experimental design, enhanced reproducibility, and greater predictive ability.
Randomization and Allocation Concealment of Animals to Intervention
The starting point for an unbiased interventional study is the use of a mechanism that ensures that the same sort of participants receive each intervention. Although researchers may argue that preclinical interventions are generally performed on a homogeneous group of animals (eg, same strain), animals may have inherent differences when the intervention is introduced (eg, age, weight, and PH severity). Several interrelated processes need to be considered to allow proper balance between groups. First, random animal allocation, if properly implemented in a large enough sample, should balance characteristics that may influence response to treatment. As such, randomization is essential to minimizing bias. However, selection bias may arise if the random allocation is not concealed. Concealment refers to techniques used to implement the allocation sequence. If future assignment can be anticipated (ie, allocation is not concealed), then selection bias may be introduced as animals may be selected based on the upcoming intervention assignment. In clinical trials, there is empirical evidence that either inadequate generation 63 or concealment 64 of allocation sequence yield to exaggerated estimates of intervention effects. Similar observations were made for preclinical research. 65, 66 Thus, the type and methods used to randomize animals to various study arms should be reported clearly. These may include (but are not limited to) the use of computerized randomization. Allocation concealment can be achieved if deidentified codes are generated and provided to team members performing group allocation. This usually entails an independent team member producing randomization sequences and lists. Finally, researchers should report measures of successful randomization by providing baseline characteristics of animals (eg, age, weight, and echocardiography parameters) in various comparison groups.
Blinding of Outcome Assessment
Blinding refers to the process by which the study personnel, including people assessing the outcomes, are kept unaware of intervention allocations. Lack of blinding in clinical trials is associated with exaggerated estimates of intervention effects, 64 especially when the outcome of interest is subjective. 67 Importantly, many apparently objective outcome measures in preclinical PAH studies remain subject to interpretation (eg, pulmonary artery remodeling and hemodynamic tracings). Thus, blinding procedures must be reported unless there is a clear rationale for the nonblinding of the experimenter (eg, surgical intervention) in which case this should be made explicit. Although blinding the investigator administering the treatment/intervention may not be possible in all instances, blinded assessment of imaging, hemodynamics, and histological outcomes is almost universally possible through independent team members performing outcome ascertainment. Even scientists of high integrity are enthusiastic supporters of their hypotheses, and unconscious bias can creep into evaluation of unblinded experiments.
Study Read-Outs and Interstudy Standardization in Preclinical PAH Studies
The primary end point of a study may be defined as the variable capable of providing the most relevant and convincing evidence directly related to the primary objective of the study. It is noteworthy that even with rigorous attention to inclusion of multiple models and both sexes and blinded assessments, results may not have translational validity if the end point specified is not valid or is not measured using robust techniques. In preclinical confirmatory studies, this outcome measure should match the clinical realm using relevant measures (eg, comprehensive hemodynamics) because nonsurrogate outcomes, such as survival, may not be approved by ethical authorities in many countries. Because multiple end points are often necessary to adequately evaluate the effects of a therapy, other read-outs are generally used to provide supportive (secondary end points) or exploratory, hypothesis-generating information. Preclinical PH interventional studies most commonly include makers of pulmonary hemodynamics (eg, right ventricular systolic pressure and mean pulmonary artery pressure) and pulmonary artery remodeling. A major value of animal studies is the ability to ensure hemodynamic end points are correlated with histological, anatomic, and biochemical findings postmortem. Nonetheless, the use of the same core set of end points in confirmatory preclinical efficacy studies in PH would clearly facilitate the comparison of results. Likewise, the use of incomplete hemodynamics and premature termination of studies based on soft end points biases studies toward positive findings and should be avoided.
As for clinical studies, the primary end point of preclinical confirmatory PH studies must be decided before the study begins because this is a prerequisite for sample size calculation. The importance of prespecified sample size calculation, referred to as a power calculation, in confirmatory experiments cannot be overemphasized, although it is rarely performed, or at least is rarely reported, in preclinical PH studies (Figure 3) . A small sample will result in an inconclusive study, whereas an unnecessary large sample size will accrue excessive costboth scenarios expending limited resources (Figure 4) . In both situations, inappropriate sample size can be judged unethical because exposing laboratory animals (as humans) to the possible risks associated with research is only justifiable if there is a realistic chance that the study will yield useful information. Although many researchers are tempted to perform interim analyses and subsequently increase the sample size as necessary, prespecified sample size calculation is mandatory to avoid the risk of false-positive results because of multiple analyses. The exploratory nature of some experiments makes formal power and sample size calculation impossible or meaningless; however, the rationale for selecting the primary outcome and the effect size of the intervention for which the study is powered should be provided in the Methods section of confirmatory experiments. The main factors that must be considered in formal hypothesis testing are the α-error, β-error, and effect size, as well as the attrition rate and SD for quantitative measurements. These values are either known from the literature or previous proof-of-concept studies or can be estimated by reasonable guesswork.
Similarly important is how the outcomes of interest are measured. In clinical trials, detailed standard operating procedures have been developed for measures that may influence study outcomes, including how the 6-minute walk test, 68 echocardiography, 69 and catheterization 70 are performed and how adverse events are reported. 71 Conversely, empirical work has confirmed marked heterogeneity in the methodologies used to assess study outcomes in preclinical PH studies. 30 Indeed, the assessment of pulmonary hemodynamics is frequently limited to right ventricular systolic pressure, whereas indirect markers of pulmonary vascular disease (eg, pulmonary vascular resistance) and right ventricular function (eg, cardiac output and end-diastolic pressure) would be readily available. It can be argued that because the most common confounder in terms of a diagnosis of group 1 PH is group 2 PH, the requirement in preclinical studies (as in clinical studies) should include measurement of left atrial or left ventricle end-diastolic pressure and calculation of pulmonary vascular resistance to exclude the possibility the observed PH is in fact because of left heart disease. This is a particular concern in genetically manipulated mouse models. In this regard, echocardiography alone Figure 4 . Precision of the effect estimate as the sample size increases. Statistical analyses are made on a study sample, which is a subset of a larger population that is collected and analyzed to make inferences. As the sample size increases, the precision of the estimates increases, assuming that the study sample was representative of the population of interest (ie, no sampling error). When comparing 2 groups as sample size increases, the calculated P value would theoretically stabilize toward its true value (gray lines). In practice, the P value erratically progresses, especially at lower sample size (black lines), particularly in the presence of outlier measurements. An underpowered study may be associated with type II error (false-negative result), whereas increasing the sample size beyond a certain point (eg, beyond 30 in the example above) would be unnecessary (A). Conversely, interim analyses may be associated with type I error (false-positive results). Indeed, using the conventional significance level of 5%, it is expected that 1 in 20 tests will be statistically significant even when there is no difference between the interventions being compared, then 0.95×0.05=0.0475 at second look (thus a total probability of 0.0975 after both analyses), assuming that the measures are independent. Thus, the nominal P values should be adjusted after conducting interim analyses if one does not want to compromise the validity or integrity of the final analyses (B).
is insufficient to exclude group 2 PH. How catheterization is performed is also frequently poorly described. However, hemodynamics should ideally be done with inhaled anesthesia in closed-chest animals to avoid artifactual reduction in pressures that accompany over sedation [72] [73] [74] or opening of the thorax ( Figure 5 ). When conducted using rigorous attention to anesthesia, a head-to-head comparison showed that the results of hemodynamics assessment of the pulmonary circulation by high fidelity cardiac catheterization, cardiac magnetic resonance imaging, and echocardiography are similar (and reproducible) in rodent models. 75 Significant heterogeneity also exists when describing pulmonary remodeling, 30 and there is no consensus on how to report adverse events, and the majority of preclinical studies fail to appropriately monitor for toxicity. To ensure comparability and reproducibility of results from different laboratories, as many variables as possible in terms of animal handling and testing need to be controlled for. Obviously, these elements cannot be unilaterally dictated but require a consensus process to take place, with experts in the field coming together to agree on best practice. Consensus and guidelines for a more harmonized, common effort in preclinical research have been developed for preclinical in vivo evaluation of pharmacological active drugs for stroke, 76 amyotrophic lateral sclerosis, 77 and multiple sclerosis 78 to name a few. Such efforts are clearly needed in PH.
Multiplicity and the Play of Chance: Interim Analyses and P Value Adjustments
Because multiple read-outs are necessary to fully evaluate pathophysiological pathways and evaluate all of the effects of interventions, multiple end points are frequently measured. However, every time statistical analyses are performed, the chance of falsely rejecting the null hypothesis is introduced. Conducting multiple tests of significance progressively increases the probability that a null hypothesis is rejected when the null hypothesis is actually true (ie, false-positive result). Using the conventional significance level of 5%, it is expected that 1 in 20 tests will be statistically significant even when there is no difference between the interventions being compared. Consideration must be given to controlling the risk of false-positive conclusions, and adjustment for multiplicity will typically be necessary. A simple solution to impose stricter control on the probability of getting a false-positive result for confirmatory studies, yet increasing the risk of type II errors (false-negative results). Several approaches have been proposed for addressing multiplicity, including the Bonferroni procedure, related stepwise approaches, and hierarchical procedures. [79] [80] [81] Similarly, interim analyses are also frequently used to incorporate what is learned during the course of a study. The simplest result of such an interim analysis is early stopping for futility or success or continuation of the study. Similar to multiple analyses, interim analyses increase the risk of falsely rejecting the null hypothesis (Figure 4) . Therefore, there is a need to adjust the nominal P values after the conduct of interim analyses if one does not want to compromise the validity or integrity of subsequent analyses. As such, researchers should avoid unplanned interim analyses, and preliminary results should be presented without formal statistical analyses unless nominal P values have been adjusted accordingly. In an attempt to maintain the validity and integrity of the final analyses, collaboration with a statistician at the design stage is crucial. Regardless of which approach is used, the selected procedure must be prespecified in the statistical analysis plan before undertaking any analyses of the data.
Interpretation of Study Results and Reporting

Incomplete Outcome Data and Handling of Missing Data
Missing outcome data, because of attrition during the study or exclusions from the analysis, raise the possibility that the observed effect estimate is biased. Attrition and exclusions frequently occur in preclinical PH studies when animals die or are withdrawn from the experiments, assessment does not provide relevant data, data are lost or unavailable, or the animals are excluded for other reasons (eg, outliers). Comprehensive reporting of the number of animals in intervention and control groups that were available for randomization, that were randomized to various treatments/control groups and included in the intervention, as well as the number of animals for which baseline data were collected, follow-up/outcomes were assessed, and were lost at any stage during the experimental process should be detailed. Researchers should consider using a flowchart showing animals at each experimental step. A timeline of experimentation is also desirable to inform whether all animals within each experimental group were analyzed together or were a composite of >1 experiment conducted at different times.
For confirmatory studies, an intention-to-treat analysis may be considered as potentially the least biased way to estimate intervention effects in randomized trials. 82 In clinical trials, empirical evidence has suggested more exaggerated effect estimates from per-protocol analyses compared with intention-to-treat analysis of the same trials. 83 The same likely applies to preclinical studies. The risk of bias from incomplete outcome data depends on several factors, including the amount and distribution of missing data across intervention arms, the reasons for missing outcome data, and the impact of including or excluding the missing data on the outcome effect estimate. However, few studies can perform true intention-to-treat analyses without imputation. This involves making assumptions about the outcomes of animals for which no outcome was recorded. Examples include imputing the last observation carried forward in which the outcome measure is assumed to hold for all subsequent outcome assessment times in case of unreliable measures (eg, echocardiographic measures) or worst-case scenario outcomes in case of an animal's death. However, statistical analyses cannot entirely compensate for missing data, and imputation rules can also lead to serious biases unless conservative methods are used. Thus, where imputation is used, both the per-protocol and the intentionto-treat analyses should be presented, and the methods and assumptions for imputing data should be defined a priori and described in the Methods section of the article.
Interpretation of the Results: What Does the P Value Tell You (and Does Not Tell You)?
The high pressure to find low P values, combined with a common misunderstanding of how to correctly interpret P values, frequently distorts the interpretation of significant results. 84 A low P value (typically ≤0.05) is considered strong evidence against the null hypothesis. However, a P value of 0.05 is frequently incorrectly interpreted as meaning that there is 95% chance that the observed difference is true, rather than as indicating a 5% probability of the observed difference (or greater) if the null hypothesis was true. The P value is not the error rate or the likelihood of making a mistake by rejecting a true null hypothesis (type I error or false-positive rate). Indeed, Sellke et al 85 estimated that a P value of 0.05 corresponds to a false-positive rate of at least 23% (and typically close to 50%). Thus, a single statistically significant hypothesis test often provides insufficient evidence to confidently discard the null hypothesis. Study replication, especially by independent investigators, thus enhances the confidence that study results are true findings ( Figure 6 ). Therefore, investing more time in replicating results (those of others, as well as our own) should be considered and incentivized. There is an obvious balance that must be achieved to meet the 3Rs of ethical animal research (ie, replacement, reduction, and refinement, which mandates to avoid unnecessary duplication with mini-mal incremental yield). One can make a compelling case that investigators should have latitude to design the studies as they wish and can afford in accordance with ethical standards, provided they draw conclusions from appropriately designed studies that will directly guide future drug development. Systematic reviews and meta-analyses of preclinical experiments could also play important roles in synthesizing these data and have been advocated as prerequisites to undertaking clinical trials. 86 
Publication Bias and Selective Reporting Bias in Preclinical PH Studies
Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results.
Publication bias generally occurs when entire studies are not published. There is a strong possibility that such studies are missing because of their uninteresting or unwelcome findings (ie, true publication bias), leading almost inevitably to major overstatements of efficacy. 87 More subtle publication biases arise when studies are published in obscure journals, rarely cited, inappropriately indexed in databases, or when publication is delayed. Interestingly, when authors were asked why they had not published their findings, the most frequent answer was that they were not interesting enough to merit publication, 88, 89 and rejection by a journal was rarely mentioned as a reason for not publishing. Therefore, selective submission by the authors rather than selective recommendations by the reviewers or selective acceptance by the editors may be the dominant contributor to publication bias. Even within a published report, those analyses with statistically significant findings are more likely to be reported, the most commonly reported reason for nonpublication of results being lack of statistical significance or limited magnitude of effects. Some journals indirectly contribute to selective reporting by restricting their page allowances or relegating less-interesting findings to the Supplement section. For the readers, it is often difficult to determine whether this is because the outcome was not measured or because the outcome was not reported. This sort of within-study publication bias may be one of the most Figure 6 . True-positive rates according to prior probability of effectiveness. A P value of 0.05 is frequently incorrectly interpreted as meaning that there is 95% chance that the observed difference is true, rather than assuming that in the event that the null hypothesis was true, you would obtain the observed difference (or more) in 5% of studies. In fact, the false-positive rate depends on various factors, including the prevalence (or prior probability) of real effects, study power, and P value. Let's imagine that based on previous experiments, a compound has a 20% probability (100 of 500 studies) of being effective in diseased animals. A P value of 0.05 (ie, 20 of 400 false-positive studies) in the in vivo study powered at 80% (ie, 80 of 100 true-positive studies) would be associated with an error estimate of 20% (ie, a 20% risk of being a false-positive result) based on effect size and variability estimated a priori. Replicating the study will then minimize the risk of false-positive results to 1.5% because the prior probability of being effective is now 80%. Increasing the study power and the P value would also increase the true-positive rate if the sample size is determined accordingly a priori.
substantial biases affecting results from individual studies, 90 including in preclinical PH research. 30 It is, therefore, imperative that analyses of confirmatory studies be determined by a prespecified statistical plan in which the primary, secondary, and hypothesis-generating measures are identified, along with the specific methods to correct for multiplicity and that the entire set of outcome measures planned a priori be reported.
Publication and selective reporting biases also prevent others from learning about negative study results. Full reporting of study findings is perhaps the most important aspect of conducting transparent preclinical research, with implications for animal ethics and research funding. Retaining negative findings also distorts the available body of evidence, which may lead to waste of time and resources for other researchers and humans being exposed to ineffective or toxic therapies. To minimize publication and reporting bias, study preregistration-a biasthwarting strategy that requires researchers to formally document analysis plans before collecting results-was developed for clinical trials. The idea behind preregistration is that publicly listing the planned experimental design and analysis limits a researcher's ability to modify them afterward-a practice that is common among researchers. Indeed, many researchers engage in some form of (usually mild and unintentional) scientific malpractice at one point or another. As a result, the International Committee of Medical Journal Editors now considers only those clinical trials for publication that have been registered before the start of patient recruitment. 91 In preclinical studies, preregistration in a public repository at the study inception is a debated issue. Some advocate that it would minimize publication and reporting biases, prevent fishing or manipulation to achieve a desired result, and provide leverage for scholars who face result-oriented pressure from financial benefactors or funding agencies. However, many researchers fear loss of the ability to protect intellectual propriety. More importantly, preregistration relies strongly on the notion that science is always confirmatory. Although it is obvious that a finding is more convincing when it was predicted, breakthrough findings have been made through exploration with limited a priori hypotheses. Imposing the restrictions that are applied to clinical trials may thus discourage exploratory research, whereas some kind of preregistration should be considered to minimize publication/reporting bias for confirmatory studies.
Call for Changes in Preclinical PH Confirmatory Studies
Scientific irreproducibility is a growing concern among academics and in the general population. 92 Poorly designed preclinical confirmatory studies likely contribute to experimental irreproducibility, wasted resources, and erroneous conclusions about the treatment effects. 93 Practical solutions to improve preclinical research quality and research translation have been proposed, 27, 28, 32 including guidelines and checklists to improve methodology and reporting, 26, 27 as well as multicentre preclinical studies, 94 systematic reviews, and meta-analyses. 86, 95 Most of these recommendations are related to good scientific practice in general and are often assumed to have been implemented in high-ranked scientific research. Indeed, reported rigor is not the same as actual rigor-a distinction that sometimes is impossible to make for the readers. However, biased effect estimates from studies that do not report important study design elements have been demonstrated, [95] [96] [97] [98] arguing for the importance of reported rigor. Nonetheless, despite widespread recognition of the importance of these experimental design elements, confirmatory preclinical PH studies rarely report having implemented stringent methodologies, and their study designs have not improved during the past decade ( Figure 3) . 29, 96, 99 Furthermore, citation counts suggest that researchers may overlook crucial methodological aspects of preclinical PH studies and that greater rigor does not necessarily translate into greater scientific influence (Figure 7) . Some reviewers are also tolerant of studies in a small number of animals of a single sex and strains or with methodological flaws described above. Journal reviewers and editors directly serve as ultimate gatekeepers of research findings. However, few journals enforce methodological and reporting guidelines for confirmatory studies, despite being associated with significant improvements in methodological quality in other fields of preclinical research. 28, 29, 100 Figure 7. Box-whisker plot of the number of citations by methodological rigor of index preclinical pulmonary hypertension study (n=135). Diamond symbol plotted at mean. Outliers identified as beyond 1.5 interquartile range. Cumulative refers to sum of randomization, blinding, sample size estimation, and inclusion of both sexes (each contributing 1 point). Adapted from Ramirez et al 29 with permission. Copyright © 2017, the American Heart Association.
Implementing such requirements in preclinical PH research will involve a major paradigm shift for scientists, their institutions, journals, and funding agencies. For instance, many researchers were trained in an era where little attention was paid to the risk of bias in preclinical science. Although most universities offer courses in applied statistics and data analysis, there is a need for science-specific training in these aspects. Similarly, experimental rigor rather than flashy results should be prioritized during the article adjudication process. It should also be recognized that more robust preclinical studies generally require more time and involve more resources. Early-career scientists may, therefore, not be expected to publish as many high-methodologically rigorous articles, which should be taken into account by academic institutions and funding agencies. This transition should, therefore, be accompanied by changes in research funding, such as those undertaken by the National Institutes of Health.
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Conclusion
In preclinical PH research, methodological sources of potential bias and imprecision are prevalent and frequently overlooked by researchers. Although unlikely to be the sole cause for clinical failures, they are likely contributors to the significant discordance between preclinical and clinical results. Concerted efforts to address this problem are needed for more effective translation of preclinical research findings into sustainable improvements in patient outcomes. Rigorous study designs, methodological standardization, appropriate data interpretation, adopting statistical analysis plans, and transparent reporting of preclinical confirmatory studies are important prerequisites for this goal. Support from all relevant stakeholders, including researchers, peer reviewers, editors, academic institutions, funding agencies, animal ethics authorities, and the industry, is thus essential to fostering drug development in PH.
